What will happen in patients with advanced nonalcoholic fatty liver disease?

Takefumi Kimura^{1

2}, Naoki Tanaka^{3

4}, Eiji Tanaka²

Affiliations

¹ Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
² Department of Internal Medicine, Division of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
³ Department of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
⁴ International Research Center for Agricultural Food Industry, Shinshu University, Matsumoto, Japan.

Editorial

Takefumi Kimura et al. Hepatobiliary Surg Nutr. 2019 Jun.

. 2019 Jun;8(3):283-285.

doi: 10.21037/hbsn.2019.01.04.

Takefumi Kimura^{1

2}, Naoki Tanaka^{3

4}, Eiji Tanaka²

¹ Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
² Department of Internal Medicine, Division of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
³ Department of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
⁴ International Research Center for Agricultural Food Industry, Shinshu University, Matsumoto, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-Fabian L, Alvarez-Quiñones Sanz M, Conde-Martin AF, De Boer B, McLeod D, Hung Chan AW, Chalasani N, George J, Adams LA, Romero-Gomez M. Vilar-Gomez E, et al. Gastroenterology. 2018 Aug;155(2):443-457.e17. doi: 10.1053/j.gastro.2018.04.034. Epub 2018 May 5. Gastroenterology. 2018. PMID: 29733831

1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. 10.1002/hep.28431 - DOI - PubMed
1. Kim D, Li AA, Gadiparthi C, et al. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology 2018;155:1154-63.e3. 10.1053/j.gastro.2018.07.008 - DOI - PMC - PubMed
1. Kimura T, Kobayashi A, Tanaka N, et al. Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection. Hepatol Res 2017;47:405-18. 10.1111/hepr.12762 - DOI - PubMed
1. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015;149:389-97.e10. 10.1053/j.gastro.2015.04.043 - DOI - PMC - PubMed
1. Fujimori N, Umemura T, Kimura T, et al. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2018;24:1239-49. 10.3748/wjg.v24.i11.1239 - DOI - PMC - PubMed